: Drug-resistant tuberculosis strains pose a significant danger to worldwide tuberculosis control disease centres. Because of the poor health care system and budget constraints in low and middle-income countries, it is difficult to identify and monitor drug resistance instances utilising drug susceptibility testing and culture. In this situation, molecular tests like CBNAAT, TRUENAT, GeneXpert, and Line probe assays appear to be a cost- effective solution. The study's goal is to see how well molecular assays and Line probe assays work in diagnosing pulmonary tuberculosis, medication resistance, and treatment outcomes in Kashmir valley patients. The current study was conducted in collaboration with the State Tuberculosis Office (STO) Kashmir and the Department of Chest Medicine, Chest Diseases Hospital (CDH), Govt. Medical College, Srinagar, and the Intermediate Reference Laboratory (IRL), State TB Training and Demonstration Centre (STDC), Chest Diseases Hospital, Srinagar. A total of 400 cases were taken for the study out of 195 known drug resistance and sensitivity in the ethnic population. Between 2017 and 2021, 195 individuals with drug-resistant TB were treated in our study. Patients ranged in age from 25 to 80 years old, with 101 patients (51.8%) being male and 101 patients (51.8%) living in rural areas. There were 135 smokers among the patients, 13 with multidrug-resistant tuberculosis, 111 with rifampicin resistance, and 42 with isoniazid resistance. Patients with tuberculosis had the following treatment outcomes: 97 patients were cured (49.7%), 13 completed therapy (6.6%), 34 patients died before the treatment was completed, 11 patients were lost to follow up (5.6%), and one patient had treatment failure. More than half of the cases resulted in treatment success, which falls short of the World Health Organization's aim of at least a 75% success rate. A considerable number of patients dropped out of treatment before it was finished. These dropouts are a severe public health threat that requires immediate attention..